News

Whitehead Institute researchers have elucidated how the growth-regulating metabolic pathway known as mTORC1 (for mechanistic target of rapamycin complex 1) senses the amino acid arginine. This nutrient sensor may represent a novel therapeutic target for controlling mTORC1, whose activity is often dysregulated in a variety of diseases, including diabetes and cancer. 

In a finding with enormous implications for cancer diagnostics and therapeutics, Whitehead Institute scientists have discovered that breaches in looping chromosomal structures known as “insulated neighborhoods” can activate oncogenes capable of fueling aggressive tumor growth. 

Over the past decade, studies have found that obesity and eating a high-fat, high-calorie diet are significant risk factors for many types of cancer. Now, a new study from Whitehead Institute and MIT’s Koch Institute for Integrative Cancer Research reveals how a high-fat diet makes the cells of the intestinal lining more likely to become cancerous.

Whitehead Institute researchers have created a hydrogel scaffold that replicates the environment found within the human breast. The scaffold supports the growth of human mammary tissue from patient-derived cells and can be used to study normal breast development as well as breast cancer initiation and progression.

The germinal centers that form in the body’s lymph nodes work as a fitness boot camp in which B cells evolve to produce antibodies of increasingly higher affinity to an invading pathogen. This new finding from Whitehead Institute scientists overturns a previously held notion that only a narrow range of B cells can survive this training and go on to secrete high-affinity antibodies. This revised understanding may aid development of effective vaccines against HIV, influenza, and other viruses that mutate rapidly.

Whitehead Institute researchers have created a new mouse-human modeling system that could be used to study neural crest development as well as the modeling of a variety of neural crest related diseases, including such cancers as melanoma and neurofibromatosis. 

A team of researchers from Whitehead Institute and Queen Mary University of London (QMUL) have identified in follicular lymphoma tumors a mutated protein that could serve as a biomarker to predict therapeutic response.

Whitehead Institute researchers have created a map of the DNA loops that comprise the three dimensional (3D) structure of the human genome and contribute to gene regulation in human embryonic stem cells. The location of genes and regulatory elements within this chromosomal framework will help scientists better navigate their genomic research, establishing relationships between mutations and disease development.

Whitehead Institute announced today that Michael W. Bonney, former Chief Executive Officer of Cubist Pharmaceuticals, has been elected to its Board of Directors.

Established in 2000 by Intel co-founder Gordon Moore and his wife Betty, the Moore Distinguished Scholars Program invites researchers of exceptional quality who are acclaimed at both the national and international levels to visit Caltech for a designated period of time.